Verona Pharma plc - American Depositary Share (VRNA): Price and Financial Metrics
GET POWR RATINGS... FREE!
VRNA POWR Grades
- Sentiment is the dimension where VRNA ranks best; there it ranks ahead of 98.03% of US stocks.
- VRNA's strongest trending metric is Stability; it's been moving down over the last 141 days.
- VRNA ranks lowest in Stability; there it ranks in the 18th percentile.
VRNA Stock Summary
- For VRNA, its debt to operating expenses ratio is greater than that reported by just 10.97% of US equities we're observing.
- VRNA's price/sales ratio is 19.7; that's higher than the P/S ratio of 94.02% of US stocks.
- The volatility of VERONA PHARMA PLC's share price is greater than that of 91.96% US stocks with at least 200 days of trading history.
- If you're looking for stocks that are quantitatively similar to VERONA PHARMA PLC, a group of peers worth examining would be CYCN, RARE, MRUS, AFMD, and FDMT.
- Visit VRNA's SEC page to see the company's official filings. To visit the company's web site, go to www.veronapharma.com.
VRNA Valuation Summary
- In comparison to the median Healthcare stock, VRNA's EV/EBIT ratio is 268.42% lower, now standing at -12.8.
- VRNA's EV/EBIT ratio has moved up 5.9 over the prior 67 months.
Below are key valuation metrics over time for VRNA.
| Stock | Date | P/S | P/B | P/E | EV/EBIT |
|---|---|---|---|---|---|
| VRNA | 2022-11-01 | 20.1 | 7.3 | -14.7 | -12.8 |
| VRNA | 2022-10-31 | 19.5 | 7.0 | -14.2 | -12.4 |
| VRNA | 2022-10-28 | 19.6 | 7.1 | -14.3 | -12.5 |
| VRNA | 2022-10-27 | 17.5 | 6.3 | -12.8 | -10.9 |
| VRNA | 2022-10-26 | 17.7 | 6.4 | -12.9 | -11.0 |
| VRNA | 2022-10-25 | 17.1 | 6.2 | -12.5 | -10.7 |
VRNA's Quality Factors
The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.- VRNA has a Quality Grade of C, ranking ahead of 31.46% of graded US stocks.
- VRNA's asset turnover comes in at 0 -- ranking 440th of 680 Pharmaceutical Products stocks.
- PPBT, TEVA, and PTE are the stocks whose asset turnover ratios are most correlated with VRNA.
The table below shows VRNA's key quality metrics over time.
| Period | Asset Turnover | Gross Margin | ROIC |
|---|---|---|---|
| 2021-06-30 | 0 | NA | -8.524 |
| 2021-03-31 | 0 | NA | -14.982 |
| 2020-12-31 | 0 | NA | -21.674 |
| 2020-09-30 | 0 | NA | -13.707 |
| 2020-06-30 | 0 | NA | -6.646 |
| 2020-06-30 | 0 | NA | -6.646 |
VRNA Stock Price Chart Interactive Chart >
VRNA Price/Volume Stats
| Current price | $22.04 | 52-week high | $26.44 |
| Prev. close | $21.42 | 52-week low | $3.41 |
| Day low | $20.80 | Volume | 724,159 |
| Day high | $22.15 | Avg. volume | 689,968 |
| 50-day MA | $18.67 | Dividend yield | N/A |
| 200-day MA | $10.35 | Market Cap | 1.67B |
Verona Pharma plc - American Depositary Share (VRNA) Company Bio
Verona Pharma plc, a clinical stage biopharmaceutical company, researches, discovers, and develops therapeutic drugs to treat respiratory diseases primarily in the United Kingdom and North America. The company’s lead product is RPL554, an inhaled dual phosphodiesterase 3 and 4 inhibitor, which is in Phase II clinical trial for the treatment of chronic obstructive pulmonary disease, cystic fibrosis, and asthma. Verona Pharma plc is based in London, the United Kingdom.
Latest VRNA News From Around the Web
Below are the latest news stories about VERONA PHARMA PLC that investors may wish to consider to help them evaluate VRNA as an investment opportunity.
Verona Pharma PLC American Depositary Share (VRNA) Stock Sinks As Market Gains: What You Should KnowVerona Pharma PLC American Depositary Share (VRNA) closed at $22.53 in the latest trading session, marking a -0.75% move from the prior day. |
Verona Pharma PLC American Depositary Share (VRNA) Dips More Than Broader Markets: What You Should KnowVerona Pharma PLC American Depositary Share (VRNA) closed at $23.69 in the latest trading session, marking a -0.96% move from the prior day. |
The Zacks Analyst Blog Highlights AVEO Pharmaceuticals, Cabaletta Bio, Verona Pharma and Wave Life SciencesAVEO Pharmaceuticals, Cabaletta Bio, Verona Pharma and Wave Life Sciences are included in this Analyst Blog. |
Why These 7 Healthcare Stocks Could Soar in 2023These healthcare stocks to buy are trading at a hefty discount and are poised to deliver robust returns in 2023. |
American Equity and Avis Budget Stock See Action From Activist InvestorsBrookfield Asset disclosed a large stake in annuity-products issuer American Equity. Hedge fund SRS Investment reached an amended standstill pact with car-rental firm Avis Budget. |
VRNA Price Returns
| 1-mo | -15.65% |
| 3-mo | 70.00% |
| 6-mo | 258.37% |
| 1-year | 254.91% |
| 3-year | 300.73% |
| 5-year | 82.15% |
| YTD | -15.65% |
| 2022 | 288.84% |
| 2021 | -4.00% |
| 2020 | 21.74% |
| 2019 | N/A |
| 2018 | 0.00% |
Loading social stream, please wait...